</>Build with Tariff Intelligence|Programmatic access to tariff calculations and HS code classification.Explore Developer Resources →

5'-[3'-(Dimethylamino)propyl]-10',11'-dihydro-5H'-dibenzo[a,d]cyclohepten-5'-ol (Dibenzcarbinol)

Dibenzcarbinol is a complex aromatic amino-alcohol serving as a pharmaceutical intermediate and research chemical. Its structure includes a dibenzocycloheptene core with a dimethylaminopropyl chain and hydroxyl group, explicitly listed under HTS 2922.19.2000 for aromatic amino-alcohols. As a separate chemically defined organic compound, it adheres to Chapter 29's provisions for oxygen-function amino-compounds.

Import Duty Rates by Country of Origin

Origin CountryMFN RateCh.99 SurchargesTotal Effective Rate
🇨🇳China5.8%5.8%
🇲🇽Mexico5.8%5.8%
🇨🇦Canada5.8%5.8%
🇩🇪Germany5.8%5.8%
🇯🇵Japan5.8%5.8%

Alternative Classifications

This product could be classified differently depending on its characteristics or intended use.

2933.99.97.01Higher: 6.5% vs 5.8%

If containing heterocyclic rings dominating classification

Heterocyclic compounds with nitrogen take precedence in 2933 over amino-alcohols if ring structure is primary feature.

2922.19Same rate: 5.8%

If non-aromatic variant or not specifically named

Other non-aromatic amino-alcohols fall in 2922.19.4000; aromatic specificity limits to .2000 for listed compounds.

2942.00Higher: 13.7% vs 5.8%

If for salts thereof when imported as such

Organic salts not elsewhere specified go to 2942, but Chapter 29 note 3(C) keeps amino-alcohol salts here.

Not sure which classification is right?

Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.

Import Tips & Compliance

Provide chemical structure diagrams and CAS number (if available) in import docs to match the precise nomenclature in 2922.19.2000

Declare as lab or industrial chemical with stabilizer if added for transport, per Chapter 29 note (f), to avoid reclassification

Watch for pharma-specific FDA regs; improper end-use claims could trigger scrutiny under medicinal headings like 3002